2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company"), a leader in the development of differentiated targeted radiotherapies, announced today that Sandesh Seth, Chairman and CEO will be ...

Q VYJUVEK revenue and $623.2 million since U.S. launch VYJUVEK launched in Germany in 3Q; launched in France and Japan in ...

TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage ... This press release may contain forward-looking statements within the meaning of Section 27A of the ...

Advisers, some employees and some board members are scoring payouts ranging from $75,000 to $53 million.

The upcoming EU Biotech Act may be more prominently focused on health. But it will also significantly impact food and food ...

Roughly 70 to 80% of ovarian cancer cases are diagnosed at an advanced stage,1 where treatment options are limited and ...

A well-crafted narrative helps investors see not just the molecule in front of them, but the broader therapeutic and ...

In the past week or so, a gold and silver miner, a struggling offshore driller, and a biotech saw some huge insider buying.

We’re talking about biotechnology and agriculture working together to figure out how we’ll feed everyone in the years to come ...

BIB ETF is best suited for high-risk, active investors in the accumulation phase or retirees managing portfolios hands-on.